Please login to the form below

Not currently logged in
Email:
Password:

Takeda appoints new financial head

François-Xavier Roger brings experience from Sanofi and in telecoms

Takeda Francois-Xavier RogerTakeda has appointed François-Xavier Roger as the company's new chief financial officer.

He will lead the integration and leadership of the finance functions across Takeda and will report to the company's president and CEO Yasuchika Hasegawa.

The move is a return to the pharma industry for Roger who was most recently chief financial officer at Millicom International Cellular, a digital and mobile telecoms company.

He gained experience in the life sciences while serving in several leadership roles at Sanofi, including time in Japan, Mexico, France and South Africa.

He has further experience in Asia as chief financial officer of Danone's operations in the Asia Pacific region based in Singapore.

“With a proven track record of global success in financial leadership positions at world-class companies in pharmaceutical and consumer product businesses, we are extremely pleased to add Roger to the senior leadership team at Takeda,” said Hasegawa.

Article by
Thomas Meek

9th September 2013

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Four Health

Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....